Chronic refractory bone infection — known as osteomyelitis — is one of the older FDA-recognized HBOT uses. The role has been settled for 30 years. HBOT is an add-on to surgery and antibiotics, never a stand-alone fix.
This page lays out the evidence for HBOT in bone infection. It covers the Marx-era protocols that still drive practice and where the data is strongest.
Quick Facts
| Field | Value |
|---|---|
| FDA approval status | Recognized indication (one of 14) |
| UHMS classification | Tier 1 — approved indication |
| Typical protocol | 2.0-2.4 ATA, 90 min, 40 sessions, daily |
| Medicare coverage | Covered under LCD L33532, 2025 for chronic refractory cases |
| Insurance prior auth | Required; surgical and antibiotic failure documented first |
| Evidence grade | GRADE C-B (large case series, no large RCT) |
The evidence
The bone infection HBOT data is built on case series and cohort studies. No large trial exists.
The Mader paper in Infect Dis Clin North Am, 1990 framed the modern case for HBOT. Mader showed that infected bone has low oxygen and that chamber breathing brings oxygen back up to a level where white cells can kill bacteria.
The Mader and Calhoun chronic case series, 1990s reported on HBOT plus surgery and antibiotics in patients who had failed standard care. Cure rates ran 70 to 85% in patients with poor wound healing.
The Marx jaw bone protocol review, 1999 set the surgery-HBOT pattern for radiation and infection of the jaw. The plan calls for 30 sessions before surgery and 10 after.
The Mader-Calhoun jaw bone series, 2003 reported on stubborn jaw infection treated with HBOT. The data supported HBOT as add-on care when surgery and drugs alone had failed.
A PMC 2013 review on HBOT for bone infection in poor-healing hosts looked at patients with diabetes, prior radiation, or poor blood flow. HBOT added clear gain in this group.
The Savvidou 2018 review on stubborn bone infection pooled the data. HBOT plus surgery and drugs beat surgery and drugs alone in poor-healing hosts.
The StatPearls 2023 reference on hyperbaric bone treatment sums up the current standard of care. The role is add-on for chronic cases.
The UHMS chapter on refractory bone infection lays out the formal indication.
A 2021 review on hyperbaric oxygen for bone infection, PMID 34390634 backed the place of HBOT in stubborn disease. The lack of large trials reflects the hard time of running such trials in this group.
The pattern is steady across 30 years. HBOT adds clear gain in poor-healing hosts with bone infection that has failed standard care. The data is large case-series and cohort work, not random.
Mechanism of action
Bone infection creates a low-oxygen zone in damaged bone. Bacteria thrive in low oxygen. The white cells that should kill them need oxygen to work.
Mader showed oxygen levels in infected bone fall to a level where white cells cannot kill bacteria. Drugs also work less well in low-oxygen tissue.
HBOT raises tissue oxygen high enough to restore white-cell killing. Several drug classes work better in well-oxygenated tissue.
HBOT also drives new blood vessel growth in damaged bone. The new vessels boost drug delivery and tissue oxygen over time.
The mechanism shows why HBOT works as an add-on, not alone. HBOT restores the setting for surgery and drugs to succeed. Without dead bone removal and bacterial cover, oxygen alone cannot resolve a deep bone case.
Typical protocol
The standard plan is 2.0 to 2.4 ATA for 90 minutes. Sessions run daily, 5 days per week, for 40 sessions total.
The Marx jaw plan uses 30 sessions before surgery and 10 after. Other body sites run a 40-session course near the surgical date.
Patients with bone infection in diabetic foot ulcers may run shorter courses tied to ulcer care. See our diabetic foot ulcer evidence atlas for the wound-care side.
The 40-session count is the highest of any HBOT use. Patients commit to about 10 weeks. Sticking with it is a real bar, mainly for working patients.
Insurance and cost
Medicare covers stubborn bone infection under CMS NCD 20.29, 2017 and the related LCD L33532. Cover asks for proof of failed surgical and drug care.
Cost per session runs $250 to $500. A 40-session course at retail rates is $10,000 to $20,000.
Most plans follow Medicare for this use. But prior auth review is strict. Plans often ask for surgical, IV drug, and ID doctor notes before they sign off.
Patients without cover face a real cost barrier. Some centers price close to Medicare rates for self-pay patients. The full course is still a big out-of-pocket spend.
Where to get it
Bone infection HBOT runs at hospital and wound-care center chambers. Referral comes from ID, ortho surgery, or wound care.
The UHMS-accredited facility directory, current 2026 lists fit centers. Most US states have at least one site able to run the full 40-session course.
For chamber type details, see our FDA-cleared chambers list. Bone infection care asks for medical chambers reaching 2.0 ATA or higher.
UHMS-accredited centers and Medicare-enrolled sites are the safer choice. See our UHMS accreditation primer for what that badge means.
Limitations and contraindications
Fresh, untreated bone infection in patients who have not had surgery is not an HBOT use. Bone cleanout and the drug course come first. HBOT is added when standard care has failed.
Untreated lung collapse is an absolute limit. So is unstable heart rhythm or seizure history.
Patients with severe lung disease may not tolerate the long course. The 40-session ask is a real medical and life-load bar.
Diabetes is not a hard limit but asks for close blood sugar checks. Chamber sessions lower blood sugar, and dose tweaks are normal.
The harder limit is the case in non-compromised hosts. The strongest data is in patients with diabetes, prior radiation, or poor blood flow. In otherwise healthy patients with first-time disease, the case for HBOT is thinner.
Active research
ClinicalTrials.gov studies on bone infection HBOT, current 2026 cover plans for diabetic foot, jaw, and spinal bone disease.
A focus area is shorter-course plans. Some trials test 20 or 30 sessions against the standard 40 to see if the shorter run is enough in select patients.
Another focus is HBOT in pediatric bone disease. The long course poses real hurdles in this group.
How this compares to off-label HBOT uses
Stubborn bone infection is one of the stronger FDA-listed HBOT uses. The mechanism is well known, the case series are large, and the role is settled as an add-on to surgery and drugs in poor-healing hosts.
This is very different from off-label HBOT for anti-aging or sports recovery. Bone-infection HBOT fixes a clear tissue oxygen gap that drives a clear clinical failure. Off-label wellness uses do not target such a gap.
For context on how off-label HBOT marketing splits from clinical data, read our analysis of institutional silence on HBOT and our late radiation tissue injury evidence atlas where the Marx setup also drives care.
The honest summary: HBOT for stubborn bone infection is well-backed as an add-on. It is not a first-line care and never alone.
Frequently asked questions
Is HBOT a replacement for surgery and antibiotics?
No. HBOT is always an add-on. Bone surgery to remove dead tissue and the IV drug course are the base. HBOT is added when those have failed or are likely to fail from poor tissue oxygen.
How long does a course take?
The standard course is 40 sessions, daily 5 days per week, running about 8 to 10 weeks. The Marx jaw plan splits this into 30 before surgery and 10 after. The long run is the highest of any HBOT use.
Which bone cases respond best?
Poor-healing hosts — those with diabetes, prior radiation, or poor blood flow — show the biggest gains. Jaw and skull cases have the longest data base. Long-bone cases in otherwise healthy patients respond less well.
Will Medicare cover this?
Yes for stubborn cases with proof of failed standard surgical and drug care. Cover is laid out in LCD L33532 and asks for ID or surgery sign-off.
Can a soft-shell wellness chamber treat this?
No. Bone infection HBOT asks for 2.0 ATA or higher in a medical chamber. Soft-shell chambers reach only 1.3 ATA. That is not enough to drive the tissue oxygen needed to back white-cell killing.
Sources
- Mader Infect Dis Clin North Am, 1990
- Mader-Calhoun Chronic Refractory Series, 1990s
- Marx Protocols Review, 1999
- Mader-Calhoun Jaw Series, 2003
- PMC Compromised Host Review, 2013
- Savvidou Refractory Osteomyelitis Review, 2018
- StatPearls Hyperbaric Bone Treatment, 2023
- PMID 34390634 Bone Infection Review, 2021
- UHMS Refractory Osteomyelitis Chapter, current
- CMS NCD 20.29 Hyperbaric Oxygen Therapy, 2017
- CMS LCD L33532, 2025
Medical disclaimer
This page is medical journalism, not medical advice. Stubborn bone infection is a serious case that asks for care from ID, surgery, and wound-care teams. HBOT is one add-on in a layered plan. It does not replace surgical care or drugs. Talk to an ID doctor about care choices.